Thymosin Alpha-1
Symbol Ta · MW 3108 Da
Thymic peptide that modulates innate and adaptive immunity.
- Discovered
- 1977
- Half-life
- 2 hours
- Approval
- Not FDA-approved in U.S.
Quick facts
- Category
- Recovery
- Route
- Injectable
- Molecular weight
- 3108 Da
- Half-life
- 2 hours
- Discovered
- 1977
- Approval status
- Not FDA-approved in U.S.
Reported effects
- Immune modulation
- Antiviral support
- T-cell function
Overview
Thymosin Alpha-1 is an immune-support peptide that helps regulate immune system activity, especially T-cell function and immune coordination. It was originally isolated from thymic tissue and has been studied for infections, immune dysfunction, and immune recovery. Unlike peptides focused on fat loss or muscle repair, Thymosin Alpha-1 is best known for immune modulation. Its purpose is to support immune balance, improve immune communication, and help the body respond more effectively to immune stress. As a recovery peptide, it is commonly associated with immune resilience, post-illness recovery, and overall immune system support.
Evidence context
Thymosin Alpha-1 evidence summary
Human clinical evidence
Thymosin Alpha-1 has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
Thymosin Alpha-1 may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for Thymosin Alpha-1 as Not FDA-approved in U.S.. The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- Common clinical/research range: 1.6 mg per dose; broader research ranges vary
- Typical Frequency
- Twice weekly is common; some protocols use more frequent dosing
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on Thymosin Alpha-1.
Internal links
Related peptides
Frequently asked questions
What category is Thymosin Alpha-1 in?
Thymosin Alpha-1 is listed in the Recovery category on Peptidic.
What route is Thymosin Alpha-1 associated with?
Thymosin Alpha-1 is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is Thymosin Alpha-1 approved?
Peptidic lists the approval status for Thymosin Alpha-1 as: Not FDA-approved in U.S.. Approval details can vary by indication and jurisdiction.
Interested in Thymosin Alpha-1?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01